{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:19:52Z","timestamp":1785161992626,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016003","name":"Istanbul University Cerrahpa\u015fa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystic fibrosis (CF) is a chronic genetic disorder characterized by pancreatic insufficiency and lung disease. Advancements in highly effective modulator therapies (HEMTs) have improved life expectancy, shifting the focus to endocrine comorbidities, such as CF-related diabetes (CFRD) and bone disease (CFRBD). Therefore, current guidelines recommend routine screening for diabetes and osteoporosis in people with cystic fibrosis (PwCF) starting from age of 10\u00a0years. Increased risk of osteoporosis has been shown in type 1 and type 2 diabetes; however, there are limited studies evaluating the impact of glucose metabolism disorders on osteoporosis in children with cystic fibrosis. Therefore, this study investigates the impact of glucose metabolism disorders on PwCF. This cross-sectional retrospective study included 81 PwCF, aged between 10 and 21\u00a0years, who were screened routinely for diabetes and bone metabolism between 2019 and 2024. Data on demographics,\n                    <jats:italic>CFTR<\/jats:italic>\n                    variants, glucose metabolism, and biochemical bone parameters, including calcium, phosphorus, ALP, PTH, vitamin D levels with bone mineral density (BMD) of L1-L4 lumber spine were analyzed. Cases were categorized as normal, indeterminate, impaired glucose tolerance (IGT), or CFRD based on OGTT. Statistical analyses were conducted to determine factors affecting BMD, including pairwise comparison and multivariate regression analysis. Of the 81 cases, 55 (67.9%) had normal glucose tolerance, 9 (11.1%) had indeterminate (INDET), 9 (11.1%) had impaired glucose tolerance (IGT), and 8 (9.9%) had CFRD. IGT and CFRD cases demonstrated significantly lower body mass index (BMI), lung function, and BMD z-score than the normal group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). HbA1c had the negative association with BMD z-score (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2009=\u2009-0.36 per %1 increase in HbA1c,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), while elevated BMI levels had positive relation (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2009=\u20090.28 per 1\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    increase in BMI,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009\n                    <jats:italic>)<\/jats:italic>\n                    . HEMT showed no significant impact on glucose or bone metabolism, likely due to short treatment durations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    : Impaired glucose metabolism has a significant association with BMD in PwCF. Integrated monitoring of glucose and bone metabolism, along with a multidisciplinary approach is essential to optimize outcomes and reduce complications.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              <jats:bold>What is Known<\/jats:bold>\n                              :\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              \u2022\n                              <jats:italic>Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in CF<\/jats:italic>\n                              .\u2022\n                              <jats:italic>Impaired glucose metabolism has been associated with reduced bone mineral density and increased fracture risk.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              <jats:bold>What is New<\/jats:bold>\n                              :\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              \u2022\n                              <jats:italic>This study demonstrates that even early glucose metabolism disorders are associated with reduced bone mineral density in CF patients<\/jats:italic>\n                              .\u2022\n                              <jats:italic>Higher HbA1c levels were found to be associated with lower bone mineral density, highlighting the relationship between hyperglycemia and bone health in CF<\/jats:italic>\n                              .\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-025-06732-2","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:40:29Z","timestamp":1768581629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between impaired glucose metabolism and bone mineral density in patients with cystic fibrosis"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-2958","authenticated-orcid":false,"given":"Mert","family":"U\u00e7ar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-3756","authenticated-orcid":false,"given":"Hande","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-7909","authenticated-orcid":false,"given":"Azer","family":"K\u0131l\u0131\u00e7 Ba\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-9223","authenticated-orcid":false,"given":"\u0130layda","family":"Altun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-3295","authenticated-orcid":false,"given":"G\u00f6k\u00e7e","family":"Velio\u011flu Ha\u015flak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2282-2606","authenticated-orcid":false,"given":"Hasan","family":"Karaka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2733-3644","authenticated-orcid":false,"given":"Zeynep","family":"Ta\u015fk\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6064-9205","authenticated-orcid":false,"given":"Dilek","family":"Bing\u00f6l Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-8820","authenticated-orcid":false,"given":"Abdurrahman Zarif","family":"G\u00fcney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-7256","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"Be\u015fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2879-8910","authenticated-orcid":false,"given":"Ay\u015fe Ayz\u0131t","family":"K\u0131l\u0131n\u00e7 Sakall\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4851-8637","authenticated-orcid":false,"given":"Olcay","family":"Evliyao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-8823","authenticated-orcid":false,"given":"Elvan","family":"Bayramo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"6732_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3","journal-title":"Lancet"},{"key":"6732_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ccm.2022.06.013","volume":"43","author":"A Kelly","year":"2022","unstructured":"Kelly A, Marks BE, Stalvey MS (2022) Endocrine complications of cystic fibrosis. Clin Chest Med 43:773\u2013789. https:\/\/doi.org\/10.1016\/j.ccm.2022.06.013","journal-title":"Clin Chest Med"},{"key":"6732_CR3","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/dc09-0586","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32:1626\u20131631. https:\/\/doi.org\/10.2337\/dc09-0586","journal-title":"Diabetes Care"},{"key":"6732_CR4","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","volume":"18","author":"KL Ode","year":"2019","unstructured":"Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL (2019) Cystic fibrosis related diabetes: medical management. J Cyst Fibros 18:S10\u2013S18. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.003","journal-title":"J Cyst Fibros"},{"key":"6732_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108703","author":"L Rakotoarisoa","year":"2024","unstructured":"Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Renaud-Picard B, Ravoninjatovo B et al (2024) Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: a five-year prospective study. J Diabetes Complications. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108703","journal-title":"J Diabetes Complications"},{"key":"6732_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","volume":"191","author":"C Lewis","year":"2015","unstructured":"Lewis C, Blackman SM, Nelson A, Oberdorfer E, Wells D, Dunitz J et al (2015) Diabetes-related mortality in adults with cystic fibrosis: role of genotype and sex. Am J Respir Crit Care Med 191:194\u2013200. https:\/\/doi.org\/10.1164\/rccm.201403-0576OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6732_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98240","author":"NJ Hart","year":"2018","unstructured":"Hart NJ, Aramandla R, Poffenberger G, Fayolle C, Thames AH, Bautista A et al (2018) Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.98240","journal-title":"JCI Insight"},{"key":"6732_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17404-z","author":"M Bogdani","year":"2017","unstructured":"Bogdani M, Blackman SM, Ridaura C, Bellocq JP, Powers AC, Aguilar-Bryan L (2017) Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-017-17404-z","journal-title":"Sci Rep"},{"key":"6732_CR9","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2327","author":"PA Gottlieb","year":"2012","unstructured":"Gottlieb PA, Yu L, Babu S, Wenzlau J, Bellin M, Frohnert BI et al (2012) No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care. https:\/\/doi.org\/10.2337\/dc11-2327","journal-title":"Diabetes Care"},{"key":"6732_CR10","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33:2697\u20132708. https:\/\/doi.org\/10.2337\/dc10-1768","journal-title":"Diabetes Care"},{"key":"6732_CR11","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","volume":"18","author":"A Anabtawi","year":"2019","unstructured":"Anabtawi A, Le T, Putman M, Tangpricha V, Bianchi ML (2019) Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications. J Cyst Fibros 18:S48-55. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.018","journal-title":"J Cyst Fibros"},{"key":"6732_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030425","author":"\u00d3 Fonseca","year":"2023","unstructured":"Fonseca \u00d3, Gomes MS, Amorim MA, Gomes AC (2023) Cystic fibrosis bone disease: the interplay between CFTR dysfunction and chronic inflammation. Biomolecules. https:\/\/doi.org\/10.3390\/biom13030425","journal-title":"Biomolecules"},{"key":"6732_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251328210","author":"C Cobb","year":"2025","unstructured":"Cobb C, Wu M, Tangpricha V (2025) Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment. Ther Adv Endocrinol Metab. https:\/\/doi.org\/10.1177\/20420188251328210","journal-title":"Ther Adv Endocrinol Metab"},{"key":"6732_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117104","author":"D Vinther","year":"2024","unstructured":"Vinther D, Thomsen RW, Furnes O, Gjertsen JE, Pedersen AB (2024) Impact of diabetes on the risk of subsequent fractures in 92,600 patients with an incident hip fracture: a Danish nationwide cohort study 2004\u20132018. Bone. https:\/\/doi.org\/10.1016\/j.bone.2024.117104","journal-title":"Bone"},{"key":"6732_CR15","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/08035250600652013","volume":"95","author":"O Neyzi","year":"2006","unstructured":"Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, Bas F (2006) Growth references for Turkish children aged 6 to 18 years. Acta Paediatrica, Int J Paediatr 95:1635\u20131641. https:\/\/doi.org\/10.1080\/08035250600652013","journal-title":"Acta Paediatrica, Int J Paediatr"},{"key":"6732_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.13453","volume":"23","author":"KL Ode","year":"2022","unstructured":"Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S et al (2022) ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 23:1212\u20131228. https:\/\/doi.org\/10.1111\/pedi.13453","journal-title":"Pediatr Diabetes"},{"key":"6732_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02078-5","author":"DS Leungsuwan","year":"2024","unstructured":"Leungsuwan DS, Chandran M (2024) Bone fragility in diabetes and its management: a narrative review. Drugs. https:\/\/doi.org\/10.1007\/s40265-024-02078-5","journal-title":"Drugs"},{"key":"6732_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100330","volume":"24","author":"P Sharma","year":"2024","unstructured":"Sharma P, Sharma RK, Gaur K (2024) Understanding the impact of diabetes on bone health: a clinical review. Metab Open 24:100330. https:\/\/doi.org\/10.1016\/j.metop.2024.100330","journal-title":"Metab Open"},{"key":"6732_CR19","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R (2019) Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. J Cyst Fibros 18:S3-9. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.016","journal-title":"J Cyst Fibros"},{"key":"6732_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2019.01.004","volume":"18","author":"IH Mathiesen","year":"2019","unstructured":"Mathiesen IH, Hitz MF, Katzenstein TL, Oturai P, Skov M, J\u00f8rgensen NR et al (2019) Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose. J Cyst Fibros 18:436\u2013441. https:\/\/doi.org\/10.1016\/j.jcf.2019.01.004","journal-title":"J Cyst Fibros"},{"key":"6732_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2265.2012.04484.x","volume":"78","author":"M Rana","year":"2013","unstructured":"Rana M, Munns CF, Selvadurai H, Briody J, Craig ME (2013) The impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis. Clin Endocrinol (Oxf) 78:36\u201342. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04484.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"6732_CR22","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.clnu.2023.07.015","volume":"42","author":"H Nayir Buyuksahin","year":"2023","unstructured":"Nayir Buyuksahin H, Dogru D, G\u00f6zmen O, Ozon A, Portakal O, Emiralioglu N et al (2023) Cystic fibrosis related bone disease in children: can it be predicted? Clin Nutr 42:1631\u20131636. https:\/\/doi.org\/10.1016\/j.clnu.2023.07.015","journal-title":"Clin Nutr"},{"key":"6732_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0740","author":"R Nagy","year":"2022","unstructured":"Nagy R, Gede N, Ocskay K, Dobai BM, Abada A, Vereczkei Z et al (2022) Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0740","journal-title":"JAMA Netw Open"},{"key":"6732_CR24","doi-asserted-by":"publisher","unstructured":"Dogru D, \u00c7ak\u0131r E, \u015ei\u015fmanlar T et al (2019) Cystic fibrosis in Turkey: first data from the national registry.\u00a0Pediatr Pulmonol\u00a01\u20138. https:\/\/doi.org\/10.1002\/ppul.24561","DOI":"10.1002\/ppul.24561"},{"key":"6732_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1651-2227.1999.tb01127.x","volume":"88","author":"D Cucinotta","year":"1999","unstructured":"Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A et al (1999) Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr 88:389\u2013393. https:\/\/doi.org\/10.1111\/j.1651-2227.1999.tb01127.x","journal-title":"Acta Paediatr"},{"key":"6732_CR26","first-page":"153","volume":"30","author":"T Ntimbane","year":"2009","unstructured":"Ntimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M et al (2009) Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev 30:153\u2013177","journal-title":"Clin Biochem Rev"},{"key":"6732_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41436-020-01073-x","volume":"23","author":"YC Lin","year":"2021","unstructured":"Lin YC, Keenan K, Gong J, Panjwani N, Avolio J, Lin F et al (2021) Cystic fibrosis\u2013related diabetes onset can be predicted using biomarkers measured at birth. Genet Med 23:927\u2013933. https:\/\/doi.org\/10.1038\/s41436-020-01073-x","journal-title":"Genet Med"},{"key":"6732_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ppul.26243","volume":"58","author":"M Gur","year":"2023","unstructured":"Gur M, Bar-Yoseph R, Hanna M, Abboud D, Keidar Z, Palchan T et al (2023) Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study. Pediatr Pulmonol 58:577\u2013584. https:\/\/doi.org\/10.1002\/ppul.26243","journal-title":"Pediatr Pulmonol"},{"key":"6732_CR29","doi-asserted-by":"publisher","first-page":"E1248","DOI":"10.1210\/clinem\/dgaa890","volume":"106","author":"MS Putman","year":"2021","unstructured":"Putman MS, Greenblatt LB, Bruce M, Joseph T, Lee H, Sawicki G et al (2021) The effects of Ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis. J Clin Endocrinol Metab 106:E1248\u2013E1261. https:\/\/doi.org\/10.1210\/clinem\/dgaa890","journal-title":"J Clin Endocrinol Metab"},{"key":"6732_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144149","author":"C Piona","year":"2022","unstructured":"Piona C, Mozzillo E, Tosco A, Volpi S, Rosanio FM, Cimbalo C et al (2022) Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11144149","journal-title":"J Clin Med"},{"key":"6732_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100307","author":"H Crow","year":"2022","unstructured":"Crow H, Bengtson C, Shi X, Graves L, Anabtawi A (2022) CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy. J Clin Transl Endocrinol. https:\/\/doi.org\/10.1016\/j.jcte.2022.100307","journal-title":"J Clin Transl Endocrinol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06732-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:19:55Z","timestamp":1772551195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06732-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6732"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06732-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7003006\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"84"}}